1. Home
  2. RYTM vs IDCC Comparison

RYTM vs IDCC Comparison

Compare RYTM & IDCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$93.66

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo InterDigital Inc.

IDCC

InterDigital Inc.

HOLD

Current Price

$286.43

Market Cap

6.6B

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYTM
IDCC
Founded
2008
1972
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Multi-Sector Companies
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
6.6B
IPO Year
2017
2007

Fundamental Metrics

Financial Performance
Metric
RYTM
IDCC
Price
$93.66
$286.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
2
Target Price
$131.14
$412.50
AVG Volume (30 Days)
555.5K
331.5K
Earning Date
05-05-2026
04-30-2026
Dividend Yield
N/A
0.79%
EPS Growth
28.34
N/A
EPS
N/A
2.14
Revenue
N/A
$307,404,000.00
Revenue This Year
$55.34
N/A
Revenue Next Year
$86.06
$3.38
P/E Ratio
N/A
$134.20
Revenue Growth
N/A
N/A
52 Week Low
$60.99
$213.06
52 Week High
$122.20
$412.60

Technical Indicators

Market Signals
Indicator
RYTM
IDCC
Relative Strength Index (RSI) 62.82 58.27
Support Level $82.43 $249.31
Resistance Level $100.69 $365.98
Average True Range (ATR) 4.46 10.57
MACD 0.64 6.17
Stochastic Oscillator 81.49 75.76

Price Performance

Historical Comparison
RYTM
IDCC

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About IDCC InterDigital Inc.

InterDigital Inc is a research and development company focused on wireless, Video, Artificial Intelligence, and related Technologies. It designs and develops technologies that enable connected, immersive experiences in a broad range of communications and entertainment products and services. The majority of revenue is generated from fixed-fee patent license agreements, with a smaller portion coming from variable royalty agreements. Geographically, it operates in the United States, China, South Korea, Japan, Taiwan, and Europe, with the majority is from China.

Share on Social Networks: